LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListBiogen Inc

Biogen Inc

Closed

Sector Healthcare

203.4 0.83

Overview

Share price change

24h

Current

Min

200.55

Max

204.68

Key metrics

By Trading Economics

Income

318M

250M

Sales

-144M

2.4B

P/E

Sector Avg

25.742

23.904

EPS

3.3

Profit margin

10.464

Employees

7,570

EBITDA

242M

652M

Recommendations

By TipRanks

Rating Consensus

Buy

12 Months Forecast

+42.05 upside

Dividends

By Dow Jones

Next earnings

23 Apr 2024

Market Stats

By TradingEconomics

Market Cap

-663M

30B

Previous open

202.57

Previous close

203.4

News Sentiment

By Acuity

36%

64%

71 / 274 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Biogen Inc chart

Related News

7 Aug 2023, 12:03 UTC

Major Market Movers

Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback

4 Oct 2023, 17:55 UTC

Acquisitions, Mergers, TakeOvers

Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment? -- IBD

1 Sept 2023, 15:23 UTC

Acquisitions, Mergers, TakeOvers

Why Amgen's $28 Billion Merger News Also Bodes Well For Pfizer, Biogen -- IBD

25 Jul 2023, 20:03 UTC

Earnings

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD

25 Jul 2023, 15:41 UTC

Top News

A Surprising Beneficiary of New Alzheimer's Drugs: GE HealthCare -- Heard on the Street -- WSJ

25 Jul 2023, 14:21 UTC

Earnings

Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD

25 Jul 2023, 13:25 UTC

Earnings

Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD

25 Jul 2023, 13:02 UTC

Earnings

Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD

19 Jun 2023, 11:00 UTC

Top News

Alzheimer's Blockbuster Is Coming, but Slowly -- Heard on the Street -- WSJ

9 Jun 2023, 11:19 UTC

Market Talk

Biogen Halted Ahead of FDA AdCom on Alzheimer's Drug -- Market Talk

3 May 2023, 14:16 UTC

Top News

Eli Lilly's Results Signal Arrival of Blockbuster New Drug Class -- Heard on the Street -- WSJ

27 Apr 2023, 11:18 UTC

Earnings

Eli Lilly Misses on Earnings. The Shares Still Rise. -- Barrons.com

26 Apr 2023, 20:30 UTC

Earnings

Eli Lilly Earnings Are Soon. All Eyes Are on Its Diabetes Drug, Mounjaro. -- Barrons.com

21 Apr 2023, 06:00 UTC

Acquisitions, Mergers, TakeOvers

Biopharma Deals Are Hot. There's More to Come -- and These Stocks Can Benefit. -- Barrons.com

Peer Comparison

Price change

Biogen Inc forecast

Price Target

By TipRanks

42.05% upside

12 Months Forecast

Average 289.32 USD  42.05%

High 400 USD

Low 215 USD

Based on 25 Wall Street analysts offering 12 month price targets for Biogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

25 ratings

17

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

200.65 / 205.36 Support&Resistance

Short Team

Weak Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

71 / 274 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.